Geode Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History
Bought
Maintained
Sold
Other funds holding BDTX
NMC
VCM
Geode Capital Management's BDTX Position: Q1 2026 in Review
Geode Capital Management increased its Black Diamond Therapeutics (BDTX) stake by 6.1% in Q1 2026, buying an estimated $73.2K and bringing the position to 536,575 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #3321.
Geode Capital Management first reported a position in BDTX in Q1 2020 and has held it in 25 quarters since. The position peaked at $8.65M in Q4 2020. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.
- Geode Capital Management held 536,575 shares of Black Diamond Therapeutics worth $1.14M as of Q1 2026.
- Geode Capital Management bought 30,795 Black Diamond Therapeutics shares in Q1 2026, an estimated $73.2K.
- Black Diamond Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3321 holding.
- Geode Capital Management first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 25 quarters since.
- Geode Capital Management's Black Diamond Therapeutics position peaked at $8.65M in Q4 2020.
- 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.
Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.